PRKAA2 and hepatocellular carcinoma: However, aldometanib was still able to activate AMPK and inhibit mTORC1 in these cells and tissues (Supplementary information, Fig. S5l–n), as this is mediated by all three isozymes of aldolase, not only ALDOB.38 These data indicate that aldometanib showed strong effects on different HCC models, including reductions in tumor size and increased wellness of the mice, with the survival of HCC mice to mature ages as the most important efficacy endpoint.